Recombinant protein · Protein replacement · developed by Ultragenyx Pharm
Vestronidase alfa is a recombinant form of human beta-glucuronidase (GUS) given to replace the deficient enzyme. Its mannose-6-phosphate residues allow uptake into cell lysosomes, where it helps break down accumulated glycosaminoglycans. It is used to treat mucopolysaccharidosis VII (Sly syndrome).
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Nov 18, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03775174 | N/A | MPS VII | Available | RARE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
MPS VIIMucopolysaccharidosis VIISly Syndrome
Updated Oct 25, 2026. Something wrong or missing? Report it on the RARE page.
See RARE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RARE catalysts and pipeline →